Palvella Therapeutics develops topical drug candidates for rare skin diseases and vascular malformations, aimed at patients and their doctors. PVLA reports earnings on Tue, Nov 10, 2026. Over the past 90 days StreetAlpha recorded 2 whale options trades in PVLA, 50% of them bullish and 50% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | HC Wainwright & Co. | Maintained | Buy | |
| Sep 21 | Chardan Capital | Maintained | Buy | |
| May 21 | Chardan Capital | Maintained | Buy | |
| May 12 | Stephens & Co. | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in PVLA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PVLA is in one of them and how their past PVLA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PVLA in an article yet. Here's the latest on the wider market.
About Palvella Therapeutics
Palvella Therapeutics is a biopharmaceutical company based in Wayne, Pennsylvania, that is developing topical treatments for rare skin diseases and vascular malformations where no approved therapies exist. Its lead candidate, a rapamycin gel called QTORIN rapamycin, is in clinical trials for microcystic lymphatic malformations and cutaneous venous malformations. The company also has a candidate in development for disseminated superficial actinic porokeratosis. Its target customers are patients with these conditions and the physicians who treat them.
- Headquarters
- Wayne, PA